rifinah
sanofi s.r.l. - rifampicina, associazioni - rifampicina, associazioni
rifater
sanofi s.r.l. - rifampicina, pirazinamide e isoniazide - rifampicina, pirazinamide e isoniazide
verzenios
eli lilly nederland b.v. - abemaciclib - neoplasie al seno - agenti antineoplastici - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
holoxan
baxter s.p.a. - ifosfamide - ifosfamide
femara
novartis farma s.p.a. - letrozolo - letrozolo
anastrozolo teva
teva italia s.r.l. - anastrozolo - anastrozolo
fareston
orion corporation - toremifene - neoplasie al seno - terapia endocrina - trattamento ormonale di prima linea del carcinoma mammario metastatico ormone-dipendente nei pazienti in postmenopausa. fareston non è raccomandato per i pazienti con il recettore per gli estrogeni negativi tumori.
aromasin
pfizer italia s.r.l. - exemestane - exemestane
fluoxetina zentiva
zentiva italia s.r.l. - fluoxetina - fluoxetina
naxestan
epionpharma srl - exemestane - exemestane